EverHint Lens - Tango Therapeutics, Inc. (TNGX) - Yahoo Finance Top Gainer Stock Analysis - March 05, 2026
Analysis Date: 2026-03-05
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
Tango Therapeutics, Inc. is currently trading at $15.80 (🟢 +27.94% today) with a market capitalization of $1.75B.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
Price & Valuation
Current Price: $15.80 (at 11:42 AM ET)
Current Volume: 6.2M
Day Range: $11.80 - $15.88
52-Week Range: $1.03 - $15.88
P/E Ratio: N/A
DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-03-05.
Market Context
Healthcare Sector: -1.33497% | Sector P/E: 32.51
Major Indices:
- S&P 500: $6817.16 (🔴 -0.76%)
- NASDAQ Composite: $22708.92 (🔴 -0.43%)
- Dow Jones Industrial Average: $47939.36 (🔴 -1.64%)
Peer Comparison
Peer comparison (11 companies):
- TNGX - Tango Therapeutics, Inc. ($15.80, +27.9%, $1.75B) ← Current
- EYPT - EyePoint Pharmaceuticals, Inc. ($16.32, -9.3%, $1.35B)
- KOD - Kodiak Sciences Inc. ($25.40, -5.4%, $1.34B)
- NRIX - Nurix Therapeutics, Inc. ($15.41, -5.3%, $1.34B)
- SEPN - Septerna, Inc. ($26.10, -9.5%, $1.17B)
- BCAX - Bicara Therapeutics Inc. Common Stock ($18.61, +0.4%, $1.02B)
- FTRE - Fortrea Holdings Inc. ($10.21, -1.6%, $944M)
- URGN - UroGen Pharma Ltd. ($19.69, -2.3%, $922M)
- XNCR - Xencor, Inc. ($11.35, -10.9%, $811M)
- KURA - Kura Oncology, Inc. ($8.24, -3.6%, $717M)
- PROK - ProKidney Corp. ($2.40, -2.6%, $674M)
Financial Performance
Latest Quarter (2025-12-31):
- Revenue: $0.00M
- Net Income: $-38.75M
- EPS: $-0.30
- Revenue Growth (QoQ): -100.0%
Earnings Calendar
Next Earnings Report: 2026-05-11 (Before Market Open)
Most Recent Report: 2026-03-05
- EPS: $-0.33 (Est: $-0.31) ✗ Miss
Historical Data: 25 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $15.00 (-5.1% upside)
- Range: $12.00 - $19.00
- Median: $14.50
Next Quarter Estimates (2027-12-30):
- Revenue: $101.02M
- EPS: $-0.41
Analyst Consensus
Overall Rating: Buy
Rating Distribution (27 total ratings):
- 🟢 Buy/Outperform: 27 (100.0%)
- ⚪ Hold/Neutral: 0 (0.0%)
- 🔴 Sell/Underperform: 0 (0.0%)
Recent Analyst Actions:
- Guggenheim (2026-02-06): Maintained Buy
- Piper Sandler (2026-01-16): Maintained Overweight
- B. Riley Securities (2025-11-18): Maintained Buy
- Guggenheim (2025-10-24): Maintained Buy
- Guggenheim (2025-08-06): Maintained Buy
Consensus based on 27 analyst ratings from major financial institutions
Trading Signals
Our technical analysis identified 5 trading signal(s) in the last 60 days:
- 2026-02-23: Momentum Swing - breakout @ $12.73
- 2026-01-09: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $11.75
- 2026-01-07: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $11.79
- 2026-01-07: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $11.79
- 2026-01-06: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $9.67
Insider Activity
Recent Transactions (Last 10):
- Buys: 5
- Sells: 5
Notable Transactions:
- 2026-02-25: Crystal Adam - Sell (Sale, 54,345 shares @ $12.77)
- 2026-02-02: Beckman Daniella - Buy (Award, 265,980 shares @ $11.94)
- 2026-02-02: Beckman Daniella - Buy (Award, 44,330 shares)
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
Overall sentiment for Tango Therapeutics (TNGX) is positive, fueled by strong clinical data from vopimetostat trials showing promising PFS and ORR, substantial $225M financing, and analyst upgrades with significant upside targets. Recent institutional buying and stock reaching 52-week highs further bolster optimism, despite isolated insider selling and a Q2 revenue dip. Conference participations and CEO transitions highlight ongoing momentum in precision oncology.
Key Themes:
- Clinical Progress
- Analyst Optimism
- Investor Activity
Sentiment: Positive (92% confidence)
Recent News
5 most recent articles covering TNGX:
- Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing (fool.com, 2026-03-04) — Read more
- Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $693,985.65 in Stock (defenseworld.net, 2026-03-02) — Read more
- Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (defenseworld.net, 2026-02-17) — Read more
- Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript (Seeking Alpha, 2026-01-14) — Read more
- Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week High – Time to Buy? (Defense World, 2026-01-10) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-05 08:42:32 AM PST
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.